US-based pain relief solutions provider Avacen Medical has secured medical device licence approval from Health Canada for its new pain treatment device, Avacen 100.

The new CE-marked device employs the firm’s new treatment method in which heat is non-invasively and safely induced into the circulatory system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The infusion of heat leads to muscular relaxation and increase of microcirculation in the body.

According to Avacen Medical chief executive officer Thomas Muehlbauer, the device allows whole body treatment with a single point of contact.

Muehlbauer said: “It is the ideal drug-free and safe alternative for relief of muscle and joint pain.

“The most exciting aspect of this approval is that the Canadian market has shown high demand and acceptance for innovative new alternatives to pharmaceuticals for treating pain.”

The firm intends to further seek Health Canada’s approval to extend the use of Avacen 100 for the treatment of fibromyalgia, which is a chronic widespread pain.

“It was found to relieve pain associated with pinched nerves, stress, panic disorder and generalised anxiety, and is also expected to provide relief from joint pain caused by CRPS, Reynaud’s and Lyme disease.”

The device was found to significantly minimise this kind of pain during a clinical study conducted in 22 subjects suffering from fibromyalgia.

It was found to relieve pain associated with pinched nerves, stress, panic disorder and generalised anxiety, and is also expected to provide relief from joint pain caused by CRPS, Reynaud’s and Lyme disease.

In addition to Health Canada, the US Food and Drug Administration (FDA), India FDA and European Union (EU) approved the device for temporary relief of minor muscle and joint pain, stiffness, muscle spasms, joint pain related to arthritis, as well as minor strains and sprains. They also approved the device for the temporary increase of local circulation and muscular relaxation.

EU approval also includes temporary relief from widespread pain and temporary increase of microcirculation.

Image: Avacen 100. Photo: courtesy of PRNewsfoto/Avacen Medical.